These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Achievement of Therapeutic Vancomycin Trough Serum Concentrations with Empiric Dosing in Neonatal Intensive Care Unit Patients. Ringenberg T; Robinson C; Meyers R; Degnan L; Shah P; Siu A; Sturgill M Pediatr Infect Dis J; 2015 Jul; 34(7):742-7. PubMed ID: 25629890 [TBL] [Abstract][Full Text] [Related]
29. Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam. Burgess LD; Drew RH Pharmacotherapy; 2014 Jul; 34(7):670-6. PubMed ID: 24855041 [TBL] [Abstract][Full Text] [Related]
30. Relationship between vancomycin-associated nephrotoxicity and the number of combined nephrotoxic agents. Ueki T; Sanematsu E; Furuya Y; Shinohara Y; Murakami Y; Miyazaki A; Sakamoto Y; Nakashima MN; Nakashima M Pharmazie; 2020 Jun; 75(6):279-283. PubMed ID: 32539926 [TBL] [Abstract][Full Text] [Related]
31. Vancomycin-induced nephrotoxicity in non-intensive care unit pediatric patients. Kwak S; Kim JY; Cho H Sci Rep; 2021 Oct; 11(1):20681. PubMed ID: 34667202 [TBL] [Abstract][Full Text] [Related]
32. The Whole Price of Vancomycin: Toxicities, Troughs, and Time. Jeffres MN Drugs; 2017 Jul; 77(11):1143-1154. PubMed ID: 28573434 [TBL] [Abstract][Full Text] [Related]
33. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Jeffres MN; Isakow W; Doherty JA; Micek ST; Kollef MH Clin Ther; 2007 Jun; 29(6):1107-15. PubMed ID: 17692725 [TBL] [Abstract][Full Text] [Related]
34. High-dose intravenous vancomycin therapy and the risk of nephrotoxicity. Rostas SE; Kubiak DW; Calderwood MS Clin Ther; 2014 Jul; 36(7):1098-101. PubMed ID: 24931573 [TBL] [Abstract][Full Text] [Related]
36. Retrospective review of vancomycin-induced nephrotoxicity in patients with leukemia. Fullmer A; McCue D; Feng C J Oncol Pharm Pract; 2014 Dec; 20(6):403-8. PubMed ID: 24177356 [TBL] [Abstract][Full Text] [Related]
37. Trough concentration over 12.1 mg/L is a major risk factor of vancomycin-related nephrotoxicity in patients with therapeutic drug monitoring. Han HK; An H; Shin KH; Shin D; Lee SH; Kim JH; Cho SH; Kang HR; Jang IJ; Yu KS; Lim KS Ther Drug Monit; 2014 Oct; 36(5):606-11. PubMed ID: 24577126 [TBL] [Abstract][Full Text] [Related]
38. Performance of a vancomycin dosage regimen developed for obese patients. Reynolds DC; Waite LH; Alexander DP; DeRyke CA Am J Health Syst Pharm; 2012 Jun; 69(11):944-50. PubMed ID: 22610026 [TBL] [Abstract][Full Text] [Related]
39. Vancomycin-induced acute kidney injury detected by a prospective pharmacovigilance program from laboratory signals. Ramírez E; Jiménez C; Borobia AM; Tong HY; Medrano N; Krauel-Bidwell L; Carcas AJ; Selgas R; Frías J Ther Drug Monit; 2013 Jun; 35(3):360-6. PubMed ID: 23666575 [TBL] [Abstract][Full Text] [Related]
40. Intravenous Vancomycin Associated With the Development of Nephrotoxicity in Patients With Class III Obesity. Choi YC; Saw S; Soliman D; Bingham AL; Pontiggia L; Hunter K; Chuang L; Siemianowski LA; Ereshefsky B; Hollands JM Ann Pharmacother; 2017 Nov; 51(11):937-944. PubMed ID: 28709394 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]